Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ellen Filvaroff

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
European Journal of Immunology|March 14, 2009
Novel therapeutic targets along the Th17 pathwayWenjun Ouyang, Ellen Filvaroff, Yan Hu, et al.
American Journal of Nephrology|December 5, 2003
Albumin stimulates the accumulation of extracellular matrix in renal tubular epithelial cellsJean-Philippe Stephan, Weiguang Mao, Ellen Filvaroff, et al.
Scientific Reports|May 11, 2023
Shallow shotgun sequencing reduces technical variation in microbiome analysisAlex J La Reau, Noah B Strom, Ellen Filvaroff, et al.
Ebiomedicine|July 3, 2015
MET Suppresses Epithelial VEGFR2 via Intracrine VEGF-induced Endoplasmic Reticulum-associated DegradationTom T Chen, Ellen Filvaroff, Jing Peng, et al.
Anti-Cancer Drugs|April 17, 2023
TACH101, a first-in-class pan-inhibitor of KDM4 histone demethylaseChandtip Chandhasin, Van Dang, Frank Perabo, et al.
Novartis Foundation Symposium|February 28, 2008
The role of Egfl7 in vascular morphogenesisMaike Schmidt, Ann De Mazière, Tanya Smyczek, et al.
Molecular Cancer Therapeutics|November 22, 2013
Nonclinical evaluation of the serum pharmacodynamic biomarkers HGF and shed MET following dosing with the anti-MET monovalent monoclonal antibody onartuzumabElaine Mai, Zhong Zheng, Youjun Chen, et al.
Cell|December 6, 2005
TWEAK attenuates the transition from innate to adaptive immunityHeather Maecker, Eugene Varfolomeev, Frank Kischkel, et al.
Neuro-Oncology|December 1, 2022
Trotabresib, an oral potent bromodomain and extraterminal inhibitor, in patients with high-grade gliomas: A phase I, "window-of-opportunity" studyVictor Moreno, Juan Manuel Sepúlveda, David A Reardon, et al.
Nature Communications|March 14, 2023
BET inhibitor trotabresib in heavily pretreated patients with solid tumors and diffuse large B-cell lymphomasVictor Moreno, Maria Vieito, Juan Manuel Sepulveda, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
European Journal of Immunology|March 14, 2009
Novel therapeutic targets along the Th17 pathwayWenjun Ouyang, Ellen Filvaroff, Yan Hu, et al.
American Journal of Nephrology|December 5, 2003
Albumin stimulates the accumulation of extracellular matrix in renal tubular epithelial cellsJean-Philippe Stephan, Weiguang Mao, Ellen Filvaroff, et al.
Scientific Reports|May 11, 2023
Shallow shotgun sequencing reduces technical variation in microbiome analysisAlex J La Reau, Noah B Strom, Ellen Filvaroff, et al.
Ebiomedicine|July 3, 2015
MET Suppresses Epithelial VEGFR2 via Intracrine VEGF-induced Endoplasmic Reticulum-associated DegradationTom T Chen, Ellen Filvaroff, Jing Peng, et al.
Anti-Cancer Drugs|April 17, 2023
TACH101, a first-in-class pan-inhibitor of KDM4 histone demethylaseChandtip Chandhasin, Van Dang, Frank Perabo, et al.
Novartis Foundation Symposium|February 28, 2008
The role of Egfl7 in vascular morphogenesisMaike Schmidt, Ann De Mazière, Tanya Smyczek, et al.
Molecular Cancer Therapeutics|November 22, 2013
Nonclinical evaluation of the serum pharmacodynamic biomarkers HGF and shed MET following dosing with the anti-MET monovalent monoclonal antibody onartuzumabElaine Mai, Zhong Zheng, Youjun Chen, et al.
Cell|December 6, 2005
TWEAK attenuates the transition from innate to adaptive immunityHeather Maecker, Eugene Varfolomeev, Frank Kischkel, et al.
Neuro-Oncology|December 1, 2022
Trotabresib, an oral potent bromodomain and extraterminal inhibitor, in patients with high-grade gliomas: A phase I, "window-of-opportunity" studyVictor Moreno, Juan Manuel Sepúlveda, David A Reardon, et al.
Nature Communications|March 14, 2023
BET inhibitor trotabresib in heavily pretreated patients with solid tumors and diffuse large B-cell lymphomasVictor Moreno, Maria Vieito, Juan Manuel Sepulveda, et al.
Pageof 2